The Recent Advances of Anti-PD-1/PD-L1 Immunotherapy
Author: 
Ze WangAuthors Info & Claims
Article No.: 27, Pages 1 - 6
Abstract
Tumor immunotherapy has demonstrated advantages over traditional therapies, and Anti-PD-1/PD-L1immunotherapy has become a hot topic in recent years and has shown excellent efficacy. A number of anti-PD-1/PD-L1 drugs have been approved for the market. This review briefly analyzes how PD-1 and PD-L1 affect the tumor immune function of human body, and the action mechanism of anti-PD-(L)1 drug from the perspective of molecular mechanism. Furthermore, it shows the clinical effect of anti-PD-(L)1 monotherapies and combination therapies by far.
References
[1]
Sharma, P. and J.P. Allison. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56--61.
[2]
Hanahan, D. and R.A. Weinberg. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646--74.
[3]
Seliger, B. (2019). Basis of PD1/PD-L1 Therapies. J Clin Med, 8(12).
[4]
G. J. Freeman et al. (2000). J. Exp. Med, 192, 1027--1034.
[5]
Li, L., et al. (2005). Rap1-GTP is a negative regulator of Th cell function and promotes the generation of CD4+CD103+ regulatory T cells in vivo. J Immunol, 175(5), 3133--9.
[6]
Dong, H., et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 8(8), 793--800.
[7]
Fabrizio, F.P., et al. (2018). Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy. Ther Adv Med Oncol, 10, 1758835918815598.
[8]
Zou, W., J.D. Wolchok, and L. Chen. (2016). PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med, 8(328), 328rv4.
[9]
Zak, K.M., et al. (2015). Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure, 23(12), 2341--2348.
[10]
Pardoll, D.M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 12(4), 252--64.
[11]
Terme, M., et al. (2011). IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res, 71(16), 5393--9.
[12]
Fanoni, D., et al. (2011). New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas. Immunol Lett, 134(2), 157--60.
[13]
Freeman, G.J., et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med, 192(7), 1027--34.
[14]
Dong, H., et al. (2003). B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med, 1999. 5(12), 1365--9.
[15]
Selenko-Gebauer, N., et al., B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol, 170(7), 3637--44.
[16]
Greenwald, R.J., G.J. Freeman, and A.H. Sharpe. (2005). The B7 family revisited. Annu Rev Immunol, 23, 515--48.
[17]
Sun, C., R. Mezzadra, and T.N. (2018). Schumacher, Regulation and Function of the PD-L1 Checkpoint. Immunity, 48(3), 434--452.
[18]
Yearley, J.H., et al. (2017). PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin Cancer Res, 23(12), 3158--3167.
[19]
Chen, D.S. and I. Mellman. (2017). Elements of cancer immunity and the cancer-immune set point. Nature, 541(7637), 321--330.
[20]
Brahmer, J.R., et al. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol, 28(19), 3167--75.
[21]
Sznol, M. et al. (2010). Safety and antitumor activity of biweekly MDX 1106 (Anti PD 1) in patients with advanced refractory malignancies. J. Clin. Oncol, 28 (Suppl.), Abstract 2506.
[22]
Ansell, S.M., et al. (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med, 372(4), 311--9.
[23]
Robert, C., et al. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med, 372(4), 320--30.
[24]
The first domestic pd-1 antibody drug triplezumab injection was approved for the market, http://www.nmpa.gov.cn/WS04/CL2094/333924.html.
[25]
Song, Y., et al. (2020). Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia, 34(2), 533--542.
[26]
Lee, H.T., S.H. Lee, and Y.S. Heo. (2019). Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. Molecules, 24(6).
[27]
Ingles Garces, A.H., et al. (2019). Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer. Expert Opin Investig Drugs, 28(8), 695--708.
[28]
Motzer, R.J., et al. (2018). Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med, 378(14), 1277--1290.
[29]
Niyongere, S., A. Saltos, and J.E. Gray. (2018). Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. J Thorac Dis, 10(Suppl 3), S433-S450.
[30]
Sahin, U., et al. (2017). Personalized RNA mutanome vaccines mobilize polyspecific therapeutic immunity against cancer. Nature, 547(7662), 222--226.
[31]
Long G V., Dummer R, Ribas A, et al. (2016). Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. J. Clin. Oncol, 34, 9568--9568.
[32]
Davies, H., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949--54.
[33]
Rini, B.I., et al. (2019). Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med, 380(12), 1116--1127.
[34]
Motzer, R.J., et al. (2019). Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med, 380(12), 1103--1115.
[35]
Junshi biotech announces a breakthrough in the combination therapy of tririplezumab (tuoyi) and acitinib, https://www.chemdrug.com/news/232/13/64283.html.
[36]
Munn, D.H., et al. (2005). GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity, 22(5), 633--42.
[37]
Gangadhar TC, Hamid O, Smith DC, et al. (2016). Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037. Ann. Oncol, 27(suppl_6).
[38]
Lee, J.Y., et al. (2016). Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun, 7, 13354.
[39]
Na, Z., et al. (2017). Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res, 27(1), 147--150.
[40]
Tan, S., et al. (2017). An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun, 8, 14369.
Index Terms
- The Recent Advances of Anti-PD-1/PD-L1 Immunotherapy
Recommendations
Discovery of small-molecule PD-1/PD-L1 antagonists through combined virtual screening and experimental validation
AbstractInhibition of the interaction between the PD-1 protein on activated lymphocytes and the PD-L1 protein on tumors represents a novel therapeutic approach for selective activation of the innate immune response against a variety of ...
Graphical AbstractDisplay Omitted
Highlights- High throughput virtual screening was used to discover novel PD-1/PD-L1 inhibitors.
Divergent Expression of PD-1 as Challenges and Chances of Immunotherapy Targeting PD-1 or PD-L1 in Cancer
Bioinformatics and Biomedical EngineeringAbstractThe effectiveness of programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) immunotherapies in cancer treatment is significantly influenced by the variable expression levels of PD-1/PD-L1. The determinants of PD-1/PD-L1 ...
Comments
Please enable JavaScript to view thecomments powered by Disqus.Information & Contributors
Information
Published In
July 2020
219 pages
Copyright © 2020 ACM.
Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than ACM must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected]
In-Cooperation
- ASciE: Association for Science and Engineering
Publisher
Association for Computing Machinery
New York, NY, United States
Publication History
Published: 21 July 2020
Check for updates
Author Tags
Qualifiers
- Research-article
- Research
- Refereed limited
Conference
BIBE2020
BIBE2020: The Fourth International Conference on Biological Information and Biomedical Engineering
July 21 - 23, 2020
Chengdu, China
Acceptance Rates
BIBE2020 Paper Acceptance Rate 36 of 116 submissions, 31%;
Overall Acceptance Rate 36 of 116 submissions, 31%
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- 0Total Citations
- 33Total Downloads
- Downloads (Last 12 months)2
- Downloads (Last 6 weeks)0
Reflects downloads up to 11 Dec 2024
Other Metrics
Citations
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Sign in